Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Liver Cancer treatment details. Chemotherapy. Chang Gung Memorial Hospital, Taipei, Taiwan Region



Survival: 4.6 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs: Adriamycin
Gemzar
Country: Taiwan Region
   
City/State/Province: Taipei
   
Hospital: Chang Gung Memorial Hospital
   
Journal: Link
   
Date: 11/2002

Description:
Patients: This Phase I-II study involved 50 patients with advanced hepatocellular (liver) carcinoma who had not received chemotherapy before. Thirty-five patients entered the Phase II portion of the study.

Treatment: Treatment consisted of two chemotherapy agents gemcitabine (gemzar) and doxorubicin (adriamycin). The Phase I part of the study involved dose escalation.

Toxicity: For Phase I at the highest dosage levels, grade 3-4 toxicities included: hematological (leucopenia, neutropenia, anemia, and thrombocytopenia) and non-hematological (i.e. mucositis, liver, neutropenic fever, and infection). For Phase II, grade 4 toxicities included: hematological (leucopenia, neutropenia, anemia, and thrombocytopenia) and non-hematological (i.e. mucositis, liver, neutropenic fever, and infection).

Results: The median survival was 4.6 months for all patients.

Support: This study was sponsored by Eli Lilly and Company. Eli Lilly markets gemcitabine

Correspondence: Dr. Cheng-Hsu Wang

E-mail to a Friend Email Physician More Information